Pressmeddelande

BioStock: Sprint Biosciences CSO comments on further VADA validation

Cision Publicerad: 08 Apr 2022 09:06

After last year’s out-licensing of Vps34, the focus is now on the next program in Sprint Bioscience’s portfolio. The VADA program has come the furthest and new research findings provide further validation to the target protein VRK1. In addition to a better understanding of the role the protein plays in cancer, the results also point to a broadened commercial potential for VADA. BioStock contacted Sprint Bioscience’s Head of Research Martin Andersson to find out more.

Read the full article at biostock.se:

https://www.biostock.se/en/2022/04/sprint-biosciences-cso-comments-on-further-vada-validation/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

Nyheter om Sprint Bioscience

Läses av andra just nu

Innehåller annonslänkar. Investeringar innebär risk (se här)

Tips: 50% rabatt hos fondroboten Opti

Dags att komma igång med sparande? Fondroboten Opti erbjuder en populär spartjänst som är perfekt för regelbundet månadssparande. Just nu får nya kunder som använder Börskollens unika kampanjkod BORSKOLLEN50 automatiskt 50 % rabatt på Optis avgift i 3 månader!